Adicet Bio

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

When did Adicet Bio become a publicly traded company?

Adicet Bio went public on NASDAQ in September 2020.

What was a significant corporate development for Adicet Bio in September 2020?

In September 2020, Adicet Bio completed a merger with resTORbio.

What was a key strategic move by Adicet Bio in 2016 regarding its presence in Israel?

In January 2016, Adicet Bio acquired the Israeli company Applied Immune Technologies (AIT), which now operates as Adicet Bio Israel, a wholly owned subsidiary.

What was the purpose of the merger agreement between resTORbio and Adicet Bio announced in April 2020?

The merger agreement between resTORbio and Adicet Bio, announced in April 2020, aimed to advance allogeneic gamma delta CAR-T cell therapy technology.

What was a notable financing event for Adicet Bio in October 2019?

In October 2019, Adicet Bio raised $80 million in a financing round, with aMoon investing.

What clinical data did Adicet Bio announce in December 2021?

In December 2021, Adicet Bio announced positive interim clinical data from its first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy.

What is Adicet Bio's primary focus in biotechnology?

Adicet Bio is a preclinical-stage biotechnology company focused on the design and development of immunotherapies for cancer and other disease indications, specifically novel universal immune cell therapies based on gamma delta T cells.

What is Adicet Bio's current market capitalization?

As of January 1, 2026, Adicet Bio's market capitalization was $1,290,411,992.

Tags